BEGIN:VCALENDAR
PRODID:-//eluceo/ical//2.0/EN
VERSION:2.0
CALSCALE:GREGORIAN
BEGIN:VEVENT
UID:5f6fbcfec4b91433d947ca0c753c36d1
DTSTAMP:20260421T200237Z
SUMMARY:Sir Ernst Chain Lecture 2024: Vaccine development in a pandemic
DESCRIPTION:Join Professor Dame Sarah Gilbert for the Sir Ernst Chain Lectu
 re 2024 from the Department of Life Sciences.\nRegister to attend on Event
 brite\nVaccine development in a pandemic\nThe 2014 outbreak of Ebola virus
  disease in West Africa highlighted the lack of preparedness for combating
  infectious disease outbreaks. Since 1976\, vaccine development had procee
 ded slowly and no candidate vaccines had progressed further than phase I t
 rials. Ebola is only one of many known viruses with the potential to cause
  outbreaks. With the support of the WHO in identifying priority pathogens\
 , and the formation of CEPI to provide funding\, vaccine development was i
 nitiated with the aim of having vaccines available in readiness for future
  disease outbreaks.\n‘Disease X’\, to represent a disease caused by a 
 previously unknown pathogen\, was also considered. In the first days of 20
 20\, the first ‘Disease X’ outbreak\, caused by a virus later named SA
 RS-CoV-2 occurred. Vaccine developers found ourselves attempting to put in
 to place plans that were at an early stage of development\, had not been f
 unded and had not therefore been tested. Rather than working to produce a 
 vaccine which could then be deployed in the ‘outbreak area’ we found o
 urselves attempting to develop a vaccine against a novel pathogen that was
  causing a pandemic whilst we ourselves were in the grip of that pandemic 
 with every aspect of our work affected.\nBiography\nProfessor Gilbert join
 ed the Nuffield Department of Medicine at Oxford University in 1994 and be
 came part of the Jenner Institute (within NDM) when it was founded in 2005
 . Her chief research interest is the development of viral vectored vaccine
 s that work by inducing strong and protective immune responses. She leads 
 work on influenza vaccine development as well as vaccines for many differe
 nt emerging pathogens\, including Nipah virus\, Middle East Respiratory Sy
 ndrome (MERS)\, and Lassa virus.\nProfessor Gilbert’s work also focuses 
 on the rapid transfer of vaccines into GMP manufacturing and first in huma
 n trials. This is achieved through collaboration with colleagues in the Cl
 inical Biomanufacturing Facility and Centre for Clinical Vaccinology and T
 ropical Medicine\, all situated on the Old Road Campus in Oxford.\nProfess
 or Gilbert is a Principal Investigator at the Pandemic Sciences Institute 
 at the University of Oxford and was the Oxford Project Leader for ChAdOx1 
 nCoV-19\, a vaccine against the novel coronavirus SARS-CoV-2. This vaccine
 \, tested by the University of Oxford in clinical trials of over 23\,000 p
 eople in the UK\, Brazil and South Africa\, was subsequently used in over 
 180 countries in the fight against the Covid-19 Pandemic is estimated to h
 ave saved more than six million lives in its first year of use.
URL:https://www.imperial.ac.uk/events/176503/sir-ernst-chain-lecture-2024-v
 accine-development-in-a-pandemic/
DTSTART;TZID=Europe/London:20240604T173000
DTEND;TZID=Europe/London:20240604T183000
LOCATION:Lecture Theatre 200\, City and Guilds Building\, South Kensington 
 Campus\, Imperial College London\, London\, SW7 2AZ\, United Kingdom
END:VEVENT
BEGIN:VTIMEZONE
TZID:Europe/London
BEGIN:DAYLIGHT
DTSTART:20240604T173000
TZNAME:BST
TZOFFSETTO:+0100
TZOFFSETFROM:+0100
END:DAYLIGHT
END:VTIMEZONE
END:VCALENDAR